IDEXX Laboratories, Inc
IDEXX Laboratories develops and sells diagnostic products and services for veterinarians, livestock producers, water testing customers, and selected human point-of-care uses. Its business is built around recurring consumables, reference lab testing, software, and service revenue that sit on top of installed diagnostic instruments and practice workflows.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueVeterinary point-of-care analyzers, consumables, rapid assays, reference lab testing, and consulting for companion animals.
Practice management systems, cloud communication tools, PACS, and diagnostic imaging systems for veterinary clinics.
Products and services used to test water for microbiological contaminants.
Diagnostic and health-monitoring products for food-animal production customers.
Human medical point-of-care diagnostics and out-licensing arrangements not reported as a core segment.
Products
Reported · share of revenue- Products59.0 %
- Services41.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
IDEXX sells primarily to veterinary practices, including general practices, specialty/referral practices, and larger group practices that need recurring diagnostics and workflow software. It also serves livestock and dairy producers, water testing users, and biomedical research customers, with a smaller human point-of-care diagnostics business. The core buying decision is driven by clinical accuracy, workflow efficiency, and the ability to generate recurring test and service revenue from installed systems.
Buy point-of-care analyzers, consumables, rapid tests, reference lab services, and software to improve diagnosis and practice economics.
Buy centralized software, imaging, and workflow tools to standardize operations across multiple locations.
Buy diagnostics and health-monitoring products to manage herd health and production outcomes.
Buy microbiological testing products to monitor water quality and contamination risk.
Buy specialized diagnostic instruments and materials for research or human testing applications.
Strategy
IDEXX is focused on expanding recurring revenue by placing instruments that drive ongoing consumable, test-kit, reference lab, and software usage. It is also investing in new products such as the inVue Dx Analyzer and AI-enabled imaging tools to deepen customer workflows and defend share in a competitive veterinary market.
Recurring consumables, test kits, and lab services carry higher margins and improve revenue visibility.
Embedding products into clinic operations raises switching costs and supports cross-sell.
New analyzers support placements that seed future recurring consumable demand.
International markets diversify growth and broaden the installed base for recurring revenue.
Geography
IDEXX has its largest business in the United States, but it also sells broadly across international markets, especially in Europe, Canada, Australia, and New Zealand. The company markets companion animal diagnostics through direct sales in the U.S. and through direct sales plus distributors in selected countries abroad, which creates some exposure to distributor inventory swings and foreign exchange. Its software and imaging offerings are also concentrated in North America, Europe, Australia, and New Zealand, while water and livestock products are sold in the U.S., Canada, and other international markets.
Risks
The company depends on continued adoption of its diagnostics and software in a competitive companion-animal market, so execution risk is tied to product innovation, pricing, and customer retention. Supply chain disruption, tariffs, foreign exchange, distributor inventory swings, and cybersecurity or IT outages can all affect revenue timing and operating performance. Regulatory requirements and patent expirations are additional constraints, although management says patent expirations are not expected to be material.
- Competitive pressure in companion-animal diagnosticsImpact: HighLikelihood: Medium
The market is attractive and draws existing competitors and new entrants, which can affect share and pricing.
Exposure: Core CAG diagnostics and software
- Supply chain and sourcing disruptionImpact: HighLikelihood: Medium
Inflation, supplier shortages, tariffs, or compliance issues can interrupt product flow and raise costs.
Exposure - Cybersecurity and IT system disruptionImpact: HighLikelihood: Medium
Software, lab services, and connected diagnostics rely on secure and continuous IT operations.
Exposure - Distributor inventory volatilityImpact: MediumLikelihood: Medium
Third-party distributor stocking can change reported sales independent of end demand.
Exposure: International companion animal products
- Foreign exchange headwindsImpact: MediumLikelihood: Low
A meaningful share of revenue is generated outside the U.S., creating translation and transaction exposure.
Exposure: International revenue and operating profit
Accounting
Judgemental itemsInstrument placements are non-recurring, while consumables, lab services, and software create recurring revenue with different timing and margin profiles.
Impact: Can shift quarterly revenue and gross margin depending on mix
International operations create translation and transaction exposure that can move reported results.
Impact: Management disclosed expected FX to reduce revenue and operating profit
Acquisitions and software/intangible assets require ongoing impairment assessment.
Impact: Potential non-cash charges if acquired assets underperform
U.S. GAAP requires judgment for allowances, contingencies, and other accruals.
Impact: Can affect reported earnings and balance sheet strength
Similar listed companies
Publicly listed companies with a comparable business focus.
IDEX Corporation
IEX · Pumps & Pumping Equipment
IDEX Corporation is a U.S.-based industrial company that designs and manufactures specialized components and subsystems for niche, mission-critical applications.
Insight Molecular Diagnostics Inc.
IMDX · In Vitro & In Vivo Diagnostic Substances
VolitionRX Limited
VNRX · In Vitro & In Vivo Diagnostic Substances
VolitionRx Ltd is a U.S.-based epigenetics diagnostics company developing blood-based tests that use nucleosomes and related biomarkers to detect and monitor disease.
MDxHealth SA
MDXH · Services-Medical Laboratories
MDxHealth SA is a molecular diagnostics company focused on tests for prostate cancer and other urologic diseases.
Aditxt, Inc.
ADTX · Pharmaceutical Preparations
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Last updated: 24/09/2026